Literature DB >> 2892251

Lack of effect of nizatidine on drug metabolism.

U Klotz1.   

Abstract

H2-receptor antagonists are among the most widely-used drugs in the world and, since many patients receive a variety of other drugs concomitantly, it is important to investigate the interaction potential of new H2-receptor antagonists such as nizatidine. It is well documented that cimetidine can inhibit the hepatic elimination of many drugs by binding to the cytochrome P-450 system. Therefore we investigated in vitro and in vivo the effects of nizatidine on drug metabolism. With rat liver microsomes the effects of nizatidine and four other H2-blockers (cimetidine, oxmetidine, ranitidine, famotidine) on the activity of three marker enzymes (aryl-hydrocarbon-hydroxylase, 7-ethoxycoumarin-O-deethylase, 7-ethoxy-resorufin-O-deethylase) were tested. While cimetidine and oxmetidine exhibited marked and dose-dependent inhibition of all three metabolic reactions, nizatidine showed some weak inhibition only at very high concentrations. Similarly, binding to cytochrome P-450 of human liver microsomes could be seen only with cimetidine and oxmetidine, whereas nizatidine did not affect the binding spectra. In nine healthy mal volunteers the pharmacokinetics of diazepam (10 mg po) was studied under the influence of nizatidine (300 mg day nocte). Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine). The formation of the major metabolite-desmethyldiazepam-was also unaffected by nizatidine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2892251     DOI: 10.3109/00365528709094481

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  11 in total

1.  Trends in Canadian tobacco consumption, 1980-89.

Authors: 
Journal:  CMAJ       Date:  1990-11-01       Impact factor: 8.262

Review 2.  Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

Authors:  A H Price; R N Brogden
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 3.  Haematological adverse effects of histamine H2-receptor antagonists.

Authors:  J P Aymard; B Aymard; P Netter; B Bannwarth; P Trechot; F Streiff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 5.  Adverse effects and drug interactions associated with local and regional anaesthesia.

Authors:  M Naguib; M M Magboul; A H Samarkandi; M Attia
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

Review 6.  Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

7.  Twenty four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 21:00 h.

Authors:  S Lanzon-Miller; R E Pounder; N A Chronos; F Raymond; M R Hamilton; D Dalgleish
Journal:  Gut       Date:  1988-10       Impact factor: 23.059

8.  Do nizatidine and cimetidine interact with ibuprofen?

Authors:  D R Forsyth; K S Jayasinghe; C J Roberts
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

9.  The liver regenerative response elicited by antisecretory agents in partially hepatectomized rats: a comparison between omeprazole and famotidine.

Authors:  T Aono
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

10.  Gastric fluid volume and pH after nizatidine in adults undergoing elective surgery: influence of timing and dose.

Authors:  K Mikawa; K Nishina; N Maekawa; M Asano; H Obara
Journal:  Can J Anaesth       Date:  1995-08       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.